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Three reference MIC methods approved by the Clinical and Laboratory Standards Institute were compared
by testing 567 staphylococci against trimethoprim-sulfamethoxazole. Category agreement ranged from 94.9%
(broth macrodilution versus broth microdilution) to 98.6% (agar dilution versus broth microdilution). Twenty-
seven strains resistant by broth macrodilution were susceptible by broth microdilution.
While it is commonly accepted that reference method results
can vary by one dilution, some antimicrobial-organism combi-
nations have even greater variability (4). Bacteriostatic antimi-
crobials such as trimethoprim-sulfamethoxazole (SXT) can
demonstrate trailing end points when reference MIC testing is
performed, especially with staphylococci (6). Trailing growth
interpretation, even by trained technologists, can be subjective,
and variations among different reference methods add to the
complexity of end point determination. A study was performed
to compare SXT MICs determined for staphylococci by three
reference methods (agar dilution [AD], broth microdilution
[BMI], and broth macrodilution [BMA]) approved by the Clin-
ical and Laboratory Standards Institute (CLSI).
A total of 567 clinical Staphylococcus strains were tested; 472
from an internal stock collection were tested, and 95 were
collected and tested externally at Barnes-Jewish Hospital, St.
Louis, MO. This set comprised 333 S. aureus isolates and 234
strains of various other Staphylococcus species (Table 1).
Several batches of AD plates and BMA tubes were prepared
internally. TREK Diagnostic Systems, Inc., Cleveland, OH,
manufactured one lot of frozen BMI panels. Quality control
was performed on each day of testing by following the guide-
lines outlined in CLSI documents (1, 2).
Fresh clinical isolates or isolates stored at 70°C were sub-
cultured twice on Trypticase soy agar containing 5% sheep
blood prior to testing. All isolates were incubated 18 to 24 h at
35°C in either ambient air or 5% CO2. The isolates were
suspended in aqueous 0.45% NaCl to achieve a turbidity equiv-
alent to a 0.5 McFarland standard and then diluted appropri-
ately and inoculated into the reference materials according to
the CLSI guidelines. All inoculated reference materials were
incubated for 16 to 20 h at 35°C in ambient air.
SXT was tested in serial twofold dilutions ranging from
0.5/9.5 to 8/152 g/ml. Results from all three MIC reference
methods were interpreted with respect to an end point of
80% reduction in growth compared to that in the positive
control (1). BMI and BMA results were read using transmitted
light; AD results were read using reflected light. All study
participants were trained to read the tests in the same manner.
The data were compiled and compared. The following CLSI
breakpoints were used: MIC of 2/38 g/ml, susceptible, and
MIC of 4/76 g/ml, resistant.
Twenty-three S. aureus strains for which differences in ref-
* Corresponding author. Mailing address: bioMe´rieux, Inc., 595 An-
glum Road, Hazelwood, MO 63042. Phone: (314) 731-7497. Fax: (314)
731-7454. E-mail: rita.griffith@na.biomerieux.com.
 Published ahead of print on 9 September 2009.
TABLE 1. Staphylococcal isolates tested
Species No. ofisolates
S. aureus ...............................................................................................333
S. auricularis ........................................................................................ 3
S. capitis ............................................................................................... 3
S. chromogenes .................................................................................... 3
S. cohnii subsp. cohnii ........................................................................ 3
S. cohnii subsp. urealyticus ................................................................. 2
S. epidermidis .......................................................................................102




S. kloosii ............................................................................................... 3
S. lentus ................................................................................................ 3
S. lugdunensis....................................................................................... 3
S. saprophyticus.................................................................................... 23
S. schleiferi ........................................................................................... 3
S. sciuri ................................................................................................. 3
S. simulans ........................................................................................... 6
S. warneri.............................................................................................. 4
S. xylosus .............................................................................................. 3
Coagulase-negative staphylococci, not otherwise specified........... 8
TABLE 2. Results from AD versus BMIa
BMI MIC
(g/ml)
No. of isolates with AD MIC (g/ml) of:
Total
0.5/9.5 1/19 2/38 4/76 8/152
0.5/9.5 425 3 428
1/19 13 12 25
2/38 2 7 3 12
4/76 5 26 10 41
8/152 3 58 61
Total 438 17 12 32 68 567
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erence MICs were greater than one doubling dilution were
typed using the DiversiLab system (bioMe´rieux, Inc., Durham,
NC). The strains were tested by following the manufacturer’s
procedure.
Tables 2 and 3 display the MIC results for comparing BMI
to AD and BMA. Results for quality control organisms S.
aureus ATCC 29213 and Enterococcus faecalis ATCC 29212
were within CLSI-published ranges for all reference testing
(data not shown).
While BMI and AD had comparable results in identifying
strains as susceptible or resistant (category agreement, 98.6%
[559 of 567 isolates were assigned to the same categories]),
BMA identified 27 strains as resistant that BMI identified as
susceptible. This outcome caused the category agreement be-
tween BMI and BMA to drop below 95% (to 94.9% [536 of 565
isolates were assigned to the same categories]). While four
errors were due to one-dilution discrepancies, the discrepan-
cies for 25 strains were greater than one dilution (Table 4). The
majority of these 25 strains were S. aureus (n  21), with the
results for one isolate each of S. cohnii subsp. cohnii, S. homi-
nis, S. saprophyticus, and S. warneri also exhibiting discrepan-
cies of greater than one dilution.
The isolates with discrepancies of greater than one dilution
were chosen for further study. Testing of these strains by the
three reference methods was repeated. The trend toward in-
creased MICs from BMA compared to those from AD and
BMI was reproduced with very few exceptions. Due to limited
materials/resources, 10 of the S. aureus isolates with discrepant
results were selected for reproducibility testing. This testing
was performed by three laboratory technicians, and isolates
were tested by the three methods for 3 days, resulting in nine
results per strain for each method. The data demonstrated that
the trend toward increased MICs from BMA compared to
those from AD and BMI was reproducible (repeat/reproduc-
TABLE 4. List of strains for which category errors are found when BMI is used as the standarda
Species Sample no.
BMI AD BMA
MIC (g/ml) Interpretation MIC (g/ml) Interpretation MIC (g/ml) Interpretation
S. aureus 7570 4/76 R 2/38 S, VME* 8/152 R
S. aureus 8753 2/38 S 1/19 S 8/152 R, ME
S. aureus 8816 2/38 S 2/38 S 8/152 R, ME
S. aureus 8865 4/76 R 2/38 S, VME* 8/152 R
S. aureus 12026 1/19 S 0.5/9.5 S 4/76 R, ME
S. aureus 12027 0.5/9.5 S 0.5/9.5 S 4/76 R, ME
S. aureus 12028 1/19 S 1/19 S 8/152 R, ME
S. aureus 12029 1/19 S 0.5/9.5 S 8/152 R, ME
S. aureus 12030 0.5/9.5 S 0.5/9.5 S 8/152 R, ME
S. aureus 12031 1/19 S 0.5/9.5 S 8/152 R, ME
S. aureus 12032 1/19 S 0.5/9.5 S 8/152 R, ME
S. aureus 12033 1/19 S 0.5/9.5 S 8/152 R, ME
S. aureus 12034 1/19 S 0.5/9.5 S 8/152 R, ME
S. aureus 12039 1/19 S 0.5/9.5 S 8/152 R, ME
S. aureus 12133 2/38 S 2/38 S 8/152 R, ME
S. aureus 12135 0.5/9.5 S 1/19 S 8/152 R, ME
S. aureus 12139 1/19 S 1/19 S 4/76 R, ME
S. aureus 12160 1/19 S 1/19 S 4/76 R, ME
S. aureus 12163 2/38 S 1/19 S 8/152 R, ME
S. aureus 12166 0.5/9.5 S 0.5/9.5 S 8/152 R, ME
S. aureus 12168 1/19 S 0.5/9.5 S 8/152 R, ME
S. aureus 13305 0.5/9.5 S 1/19 S 8/152 R, ME
S. aureus B111 1/19 S 0.5/9.5 S 4/76 R, ME
S. cohnii subsp. cohnii 9414 2/38 S 2/38 S 8/152 R, ME
S. epidermidis 7109 2/38 S 4/76 R, ME* 4/76 R, ME*
S. epidermidis 8568 2/38 S 4/76 R, ME* 2/38 S
S. epidermidis 12040 2/38 S 4/76 R, ME* 4/76 R, ME*
S. epidermidis 13204 4/76 R 2/38 S, VME* 8/152 R
S. epidermidis 13298 4/76 R 2/38 S, VME* 4/76 R
S. epidermidis 13299 4/76 R 2/38 S, VME* 2/38 S, VME*
S. hominis 12038 0.5/9.5 S 0.5/9.5 S 8/152 R, ME
S. hominis 13971 4/76 R 4/76 R 2/38 S, VME*
S. saprophyticus 12037 2/38 S 2/38 S 8/152 R, ME
S. warneri 12035 0.5/9.5 S 0.5/9.5 S 8/152 R, ME
a *, one-doubling-dilution category error; ME, major error; VME, very major error; S, susceptible; R, resistant.
TABLE 3. Results from BMA versus BMIa
BMI MIC
(g/ml)
No. of isolates with BMA MIC (g/ml) of:
Total
0.5/9.5 1/19 2/38 4/76 8/152
0.5/9.5 410 8 1 1 6 426
1/19 10 3 4 8 25
2/38 4 2 6 12
4/76 2 27 12 41
8/152 1 60 61
Total 410 18 10 35 92 565
a CLSI breakpoints are as follows: MIC 2/38 g/ml, susceptible; MIC 4/76
g/ml, resistant.
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ibility data not shown). Sterility testing was also performed; no
contamination was found in the reference materials. The same
10 isolates were sent to the ICARE laboratory at Emory Uni-
versity’s Rollins School of Public Health for BMI and molec-
ular testing. ICARE confirmed that these isolates were iden-
tified as susceptible to SXT when tested by the BMI method
(data not shown). Testing of these isolates for dfrA, which
confers trimethoprim resistance, was also performed, with
seven isolates yielding positive results while three were nega-
tive. These findings suggest that dfrA was not solely responsible
for SXT resistance.
The discrepancy in results from the different methods may
be explained by the observation that results from the BMA
method are easier to read, since an 80% growth reduction
standard can be made by mixing 2 ml of the positive control
tube with 8 ml of uninoculated broth. Test samples can then be
compared to the 80% growth reduction standard against a
lined sheet of paper to evaluate turbidity differences more
objectively. BMI is similar in that an 80% reduction control
well can be made, but the BMI end point is still more subjec-
tive to read than the BMA end point. AD results are the most
difficult to interpret, as it is not possible to make an 80%
reduction control for comparison. The BMA method may, in
theory, allow for resistance to be expressed differently than it is
in other growth media, although no studies were done to in-
vestigate whether this was the case. It is impossible to conclude
which method gives the correct MIC since all are approved
reference methods for determining MICs. Clinical outcome
data were not available for this study.
To investigate the possibility that the strains with discrepant
results were genetically related, repetitive-sequence-based
PCR using the DiversiLab system was performed. The Diversi-
Lab system works by using an optimized repetitive-sequence-
based PCR method, Agilent Lab-on-a-Chip electrophoresis
and detection, and computerized electropherogram matching
(3). The 23 S. aureus strains with discrepant results were sep-
arated into seven distinct genotypic groups. Of these groups,
four were distinct from any of the USA PFGE types or the
Iberian or Brazilian strains (5). One group containing three
strains was similar to the Iberian clone, and one strain was
similar to USA 100. It appeared that 13 (56.5%) of the 23
strains belonged to one related group, and 8 (61.5%) of those
13 strains came from one site. These 13 strains were indistin-
guishable from representatives of PFGE type USA 100 by the
DiversiLab system. Thus, although there appeared to be a
clone of highly related organisms within this test set, six unre-
lated genotypic groups also showed discrepant results.
Reference method variability is of greatest concern when the
variation occurs around the breakpoint and no intermediate
category exists, giving the appearance that an isolate is chang-
ing from susceptible to resistant or vice versa when in fact the
true MIC for the isolate may place it somewhere in between.
The data shown here indicate that laboratory personnel should
be aware that even CLSI-approved reference methods can give
different MICs for the same isolate, particularly for bacterio-
static antimicrobials such as SXT. In addition, care must be
taken that trailing end points are read consistently among
laboratory personnel in order to minimize variability. In many
cases, the clinical relevance of the differences among MIC
reference methods has not been determined.
We thank Amy Doan and Shirley Messina-Powell from bioMe´rieux,
Inc., for their technical support.
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